Many women are requesting tests to screen for ovarian cancer. Extensiv
e media coverage of this disease probably stimulates demand for these
tests. Published reports from ovarian cancer screening programs have n
ot yet demonstrated any benefit of screening. Existing programs have l
argely reported only the number of cancers detected during a single ro
und of screening. Among 36,000 screened subjects reported on, 29 ovari
an cancers have been detected; 12 of these were Stage I. All programs
report that considerable surgery for benign disease has occurred among
subjects. Follow-up, thus far, has been brief, and no control groups
are included. Several new screening programs include only women with a
family history of ovarian cancer. These programs also lack control gr
oups and have little foIlow-up to date. A prospective, randomized tria
l of ovarian cancer screening to include 74,000 postmenopausal women h
as been initiated by NCI as part of the PLCO trial. Results from this
trial should quantify the risks and benefits of screening; however, re
sults will not be available for many years. Until there are data to sh
ow that screening reduces mortality from ovarian cancer, clinicians sh
ould not suggest these tests are beneficial, and they should avoid per
forming these tests outside of research protocols. (C) 1994 Academic P
ress, Inc.